JP2015508903A - 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ - Google Patents

前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ Download PDF

Info

Publication number
JP2015508903A
JP2015508903A JP2014559890A JP2014559890A JP2015508903A JP 2015508903 A JP2015508903 A JP 2015508903A JP 2014559890 A JP2014559890 A JP 2014559890A JP 2014559890 A JP2014559890 A JP 2014559890A JP 2015508903 A JP2015508903 A JP 2015508903A
Authority
JP
Japan
Prior art keywords
psma
imaging
patient
prostate cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014559890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508903A5 (cg-RX-API-DMAC7.html
Inventor
バンダー，ニール・エイチ
Original Assignee
コーネル ユニヴァーシティー
コーネル ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル ユニヴァーシティー, コーネル ユニヴァーシティー filed Critical コーネル ユニヴァーシティー
Publication of JP2015508903A publication Critical patent/JP2015508903A/ja
Publication of JP2015508903A5 publication Critical patent/JP2015508903A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014559890A 2012-02-28 2013-02-27 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ Pending JP2015508903A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604039P 2012-02-28 2012-02-28
US61/604,039 2012-02-28
PCT/US2013/000051 WO2013130177A1 (en) 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer

Publications (2)

Publication Number Publication Date
JP2015508903A true JP2015508903A (ja) 2015-03-23
JP2015508903A5 JP2015508903A5 (cg-RX-API-DMAC7.html) 2016-04-14

Family

ID=49083148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014559890A Pending JP2015508903A (ja) 2012-02-28 2013-02-27 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ

Country Status (6)

Country Link
US (1) US20130315830A1 (cg-RX-API-DMAC7.html)
EP (1) EP2819704A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015508903A (cg-RX-API-DMAC7.html)
CA (1) CA2865774A1 (cg-RX-API-DMAC7.html)
HK (1) HK1202256A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013130177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
MX2018001566A (es) 2015-08-07 2019-04-25 Imaginab Inc Construcciones de union a antigeno para moleculas diana.
JP2020505034A (ja) 2017-01-20 2020-02-20 ジュノ セラピューティクス ゲーエムベーハー 細胞表面コンジュゲートならびに関連する細胞組成物および方法
AU2018250336B2 (en) 2017-04-07 2025-02-20 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
CA3113080A1 (en) * 2018-09-28 2020-04-02 Imaginab, Inc. Cd8 imaging constructs and methods of use thereof
WO2022114675A1 (ko) * 2020-11-24 2022-06-02 한국과학기술연구원 전립선암 진단을 위한 바이오마커, 이들의 조합, 및 이의 용도
EP4267969A4 (en) * 2020-12-22 2025-02-12 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF PROSTATE CANCER

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507857A (ja) * 2001-02-07 2005-03-24 ベズ イズレイル ディーコネス メディカル センター 改変ｐｓｍａリガンド及びそれに関する利用
JP2009530645A (ja) * 2006-03-21 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎ−カドヘリンおよびｌｙ６−ｅ：癌の診断および治療のための標的
US20100209343A1 (en) * 2009-02-17 2010-08-19 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
JP2010540657A (ja) * 2007-10-03 2010-12-24 コーネル ユニヴァーシティー Ｐｓｍａ抗体を用いる増殖性障害の治療
US20120009121A1 (en) * 2009-03-19 2012-01-12 The Johns Hopkins University Psma-targeting compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047166A1 (en) * 2008-08-20 2010-02-25 Kanner Steven B Antibodies and related molecules that bind to 58p1d12 proteins
WO2010119001A1 (en) * 2009-04-14 2010-10-21 Institut Gustave Roussy Prostate cancer cell lines and their use in screening method
EP2817629A4 (en) * 2012-02-24 2016-01-13 Univ Cornell INCREASED PSMA VALUE AS IDENTIFIER OF DEADLY PROSTATE CANCER

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507857A (ja) * 2001-02-07 2005-03-24 ベズ イズレイル ディーコネス メディカル センター 改変ｐｓｍａリガンド及びそれに関する利用
JP2009530645A (ja) * 2006-03-21 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎ−カドヘリンおよびｌｙ６−ｅ：癌の診断および治療のための標的
JP2010540657A (ja) * 2007-10-03 2010-12-24 コーネル ユニヴァーシティー Ｐｓｍａ抗体を用いる増殖性障害の治療
US20100209343A1 (en) * 2009-02-17 2010-08-19 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US20120009121A1 (en) * 2009-03-19 2012-01-12 The Johns Hopkins University Psma-targeting compounds and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BELTRAN, H. ET AL.: "Molecular characterization of neuroendocrine Prostate cancer and identification of new Drug Targets", CANCER DISCOVERY, vol. 1, no. 6, JPN6017042419, 2011, pages 487 - 495, ISSN: 0003833599 *
EVANS, M. J. ET AL.: "Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical", PNAS, vol. 108, no. 23, JPN6017042418, 2011, pages 9578 - 9582, ISSN: 0003833598 *
TAI, S. ET AL.: "PC3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma", THE PROSTATE, vol. 71, JPN6017042420, 2011, pages 1668 - 1679, ISSN: 0003833600 *

Also Published As

Publication number Publication date
US20130315830A1 (en) 2013-11-28
EP2819704A4 (en) 2015-10-21
CA2865774A1 (en) 2013-09-06
EP2819704A1 (en) 2015-01-07
HK1202256A1 (en) 2015-09-25
WO2013130177A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
Chen et al. TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency
US20250230259A1 (en) Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability
Cochrane et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Adam-Artigues et al. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
JP2015508903A (ja) 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ
Prosniak et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers
Liu et al. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer
Blake et al. G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance
Suwa et al. SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization
Tu et al. Significance of human epidermal growth factor receptor 2 expression in colorectal cancer
Wang et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts
Liu et al. Identification of PHB2 as a potential biomarker of luminal a breast cancer cells using a cell-specific aptamer
Gayed et al. Digoxin inhibits blood vessel density and HIF‐1a expression in castration‐resistant C4‐2 xenograft prostate tumors
Jachin et al. The role of nuclear EpICD in extrahepatic cholangiocarcinoma: Association with β-catenin
Ke et al. Mechanical signal modulates prostate cancer immune escape by USP8-mediated ubiquitination-dependent degradation of PD-L1 and MHC-1
Liu et al. Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients
US20200246313A1 (en) Methods for diagnosing and treating prostate cancer
Chocarro-Calvo et al. Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progression
Zhang et al. Secreted CLU is associated with the initiation of triple-negative breast cancer
Srivastava et al. Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients
US20170336422A1 (en) Method for the detection of hormone sensitive disease progression
Surve et al. Signaling events at TMEM doorways provide potential targets for inhibiting breast cancer dissemination
최연주 Prognostic and Therapeutic Implications of Nuclear Receptors and Glucose Metabolism in Sebaceous Carcinoma
He et al. Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy
Tian et al. Reptin regulates tumor cell growth and cisplatin resistance in osteosarcoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180706